PolymarketFechadoVerificar disponibilidadeSem KYC2% de taxaDados de resolução verificadosRazoavelmente calibradoEste mercado foi resolvido: Yes
Resolvido: 28 de jun. de 2026, 23:21
Resolução verificada pelo provedor
A CoinRithm tem evidência do provedor para o vencedor e o horário de liquidação deste mercado.
Resultado Vencedor
Yes
A 7 dias
—
A 24 horas
—
Probabilidade implícita atual
Sim 100%+0.0pt
Qualidade do mercado
≤49 / 100
Baixa qualidadeVolume 24h
4,8 mil €
Liquidez
—
Liquidez desconhecidaCompra / Venda
99.9% / 100.0%
Spread
0.1 pt
Spread apertadoVariação 7d
+26.9 pts
Dados do mercado
Atualizado há 64 dias
Desatualizado4/06/26, 19:5430/06/26, 0:00
Linha do Tempo de Probabilidade
No0%
Yes100%
100%
0%
Regras
As of market creation, the FDA's expected decision date for the specified application is June 30, 2026.
- This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants full or conditional approval for Viridian Therapeutics's Veligrotug as a treatment for thyroid eye disease by July 14, 2026, 11:59 PM ET.
- Otherwise, this market will resolve to "No."
- An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application
- The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs
